



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>6</sup> :</b> <b>A61K 9/00, 9/20, 9/16</b>	<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 98/17250</b> <b>(43) International Publication Date:</b> 30 April 1998 (30.04.98)
<b>(21) International Application Number:</b> PCT/EP97/05863 <b>(22) International Filing Date:</b> 23 October 1997 (23.10.97) <b>(30) Priority Data:</b> 9622090.0                      23 October 1996 (23.10.96)                      GB <b>(71) Applicant (for all designated States except US):</b> EURAND INTERNATIONAL S.P.A. [IT/IT]; Via Martin Luther King, 13, I-20060 Pessano con Bornago (IT). <b>(72) Inventors; and</b> <b>(75) Inventors/Applicants (for US only):</b> CALANCHI, Massimo, Maria [IT/IT]; Via Calatafimi, 12, I-20052 Monza (IT). MARCONI, Marco, Giuseppe, Raffaele [IT/IT]; Via Lincoln, 22, I-20092 Cinisello B (IT). MAPELLI, Luigi, Giovanni [IT/IT]; Via Bettino da Trezzo, 14, I-20125 Milano (IT). <b>(74) Agents:</b> CONNELLY, Michael, John et al.; Wyeth Laboratories, Huntercombe Lane South, Taplow, Maidenhead, Berkshire SL6 0PH (GB).		<b>(81) Designated States:</b> AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).  <b>Published</b> <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
<b>(54) Title:</b> PHARMACEUTICAL COMPOSITION FOR RAPID SUSPENSION IN AQUEOUS MEDIA <b>(57) Abstract</b> <p>The invention provides a granular composition useful as a pharmaceutical carrier which can be used for the preparation of pharmaceutical compositions that are capable of rapid suspension in water or aqueous media including saliva. The compositions may be used by addition to a glass of water with stirring or taken directly in the mouth. The granular composition may be prepared by a process which comprises subjecting a mixture of a thickening agent and a disintegrating agent to wet granulation with an aqueous medium as wetting agent or dry granulation to make a novel granular product and preparing the pharmaceutical composition from the granular product and the drug. A water-soluble inert excipient, which may be a sugar, may be mixed with the granular product prior to mixing with the drug.</p>		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav	TM	Turkmenistan
BF	Burkina Faso	GR	Greece		Republic of Macedonia	TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's	NZ	New Zealand		
CM	Cameroon		Republic of Korea	PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakhstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

PHARMACEUTICAL COMPOSITION FOR RAPID SUSPENSION IN  
AQUEOUS MEDIA

5 The present invention relates to a process for the preparation of a pharmaceutical formulation suitable for the administration of drugs and in particular of microcapsules of drugs in a monodose sachet form, the contents of which form a rapid suspension in water or an aqueous medium, for instance, saliva in the mouth.

10 In the description and the claims which follow we will use mostly the terms microcapsules or microcapsulated drugs, but the present invention can also be applied to solid drugs particles (powders, crystals, granules) which are insoluble or slightly soluble in water or drinkable aqueous liquids (milk, fruit juices, etc.) and of which one desires to obtain an extemporary and homogeneous suspension.

15 In the following description and claims the term:

- "microcapsule" is used to indicate drug particles, powders, crystals, granules, pellets and also liquid drops, coated in a polymeric membrane.
  - "microencapsulation" is generically the process used for the application of a membrane.
  - "pack or monodose sachet" is a container which contains a single dose of drug plus the
- 20 excipients of the formulation.
- "thickening or suspending substances" are substances which dissolve in water and which increase in density and viscosity allowing solid particles to be suspended.

25 Microencapsulation is a process known from some time and consists of coating substances with a continuous film based on natural or synthetic polymers.

The processes of microencapsulation are numerous. Many of these and the relative patents are cited and described in the volumes "Microcapsules and microencapsulation Techniques" (published in 1976) and "Microcapsules and other Capsules. Advance since

30 1975" (published in 1979) both by M.H. Guttcho. Among the preferred processes are those described in the U.S.A. patents 3,196,827 and 3,253,944 by D.E. Wurster which described methods of mechanical coating consisting of spraying a membrane around particles using suitable apparatus, and those cited in U.S.A. patents 3,415,758, 3,155,590 and 3,341,416 which described methods of chemico-physical coating based on the

35 coacervation or separation of phases, in which polymer making up the membrane is

-2-

dissolved in a suitable solvent or vehicle of microencapsulation and the substance to be dissolved is suspended in this solution and kept in agitation.

5 The coacervation of the polymer around the substance to be coated is obtained in various manners, such as for example temperature variation, addition of another more soluble polymer in the vehicle, addition of a non solvent of the polymer constituting the membrane, etc. The membrane can be hardened and so the microcapsules are separated from the vehicle for example by filtration or centrifuging and finally drying.

10 In the pharmaceutical field, microencapsulation is used to mask unpleasant tastes, for slowing down the release of the drug, for preventing irritation arising from contact of the drugs with the gastrointestinal mucosa, for protecting drugs from degradation, for separating drugs which react with each other, for transforming the drug into a more easily used form, such as for example, converting it from a liquid state into a powder  
15 composed of microcapsules.

A common form of dosage for the oral administration of drugs, and especially of microencapsulation drugs, is that of monodose sachets. This moreover is the most convenient solution, if not the only one, if one must administer high doses of drugs.  
20 Monodose sachets containing microcapsules have been prepared in the past, sometimes also on an industrial scale, as cited in the volume "Microencapsulation" by J. R. Nixon, Chapter 7, page 93.

25 However, they often present various disadvantages due especially to the hydrorepulsion of polymers making up the microcapsule membrane (for example polymers with a base of cellulose or waxy substances) and to the specific weight of the microencapsulated substances and therefore of the said microcapsules.

30 In fact when the contents of the sachets were poured out, as usual, in a glass of water or in fruit juice or in milk, the microcapsules formed a sediment on the bottom of the glass or floated on the surface, adhering partly to the walls of the said glass: This brought a notable inaccuracy to the quantity of the drug taken as well as poor acceptance by the patient who saw the particles floating or felt unpleasant scraping sensation in the mouth or throat when swallowing the contents at the bottom of the glass where the mass of  
35 sedimented particles was found.

The addition of thickening substances would delay and maybe also eliminate the separation of the microcapsules, but in practice has given negative results because these substances tend to form lumps on contact with water which dissolve slowly and only by resorting to vigorous mechanical agitation. It was attempted to disperse these thickening substances together with other components of the formula by mixing them in the usual powder mixers. Also with this method the formation of lumps could not be avoided, but was only partly reduced.

The above mentioned difficulties were mainly solved by the invention described in Italian patent no. 1183574 which refers to a formulation, and a method for obtaining it, characterised in that:

- 1) a thickening agent is micronized;
- 2) the thickening agent is suspended in an organic solution also containing a binding agent;
- 3) this suspension is applied by spraying it on to the surface of a substance which is easily soluble in water (sugar, sorbitol); and
- 4) the product obtaining is dried and once mixed with the microcapsules and the flavouring is used for filling the monodose sachets.

When the contents of the sachets are poured in water and agitated, as described in the examples of the patents cited, in about 1 minute a homogeneous microcapsule suspension is obtained.

In practice however it is seen that the patients, after having poured the sachet contents into water, do not stir with a spoon for at least 60 seconds, but stop after 20-30 seconds at the most. After this time the thickener is still not sufficiently dissolved and so a homogeneous suspension is not obtained and the previously cited difficulties are only partially eliminated.

WO 92/00731 discloses a system which reduces the mixing times. It was found that if an acid and a base substance are added, the thickening of the liquid and the homogeneous suspension of the microcapsules is generally obtained by mixing for only 15-20 seconds. The solid pharmaceutical composition for addition to water to produce a suspension of a drug comprises:

- a) a drug which is substantially water-insoluble or microencapsuled;
- b) a thickening or suspending agent;
- 5 c) a pharmaceutically acceptable acid;
- d) a pharmaceutically acceptable carbonate or bicarbonate. The weight ratio of c +  
d : b is from 1 : 1.5 to 1 : 15 and the amount of c + d is sufficient to obtain rapid  
10 hydration of the thickening or suspending agent b) when the composition is  
mixed with water such that a homogeneous suspension of the drug is obtained  
with 30 seconds.

WO 92/00731 states that it is necessary that the acid and base substances, are very  
thoroughly mixed with the thickening substance and therefore they must be soluble, or  
15 suspended in the form of micronized powder, in the organic solvent used for applying of  
the suspension containing the thickener.

The process disclosed in WO 92/00731 has the disadvantage of using an organic solvent  
which may cause a problem as a result of flammability or pollution. The process also  
20 has the disadvantage of being an manufacturing method with the disadvantage of a low  
concentration of thickening agent. In consequence, in order to reach a viscosity suitable  
for maintaining the microcapsules in a homogeneous suspension, monodose sachets had  
to be filled with a large amount of ingredients which also caused high costs.

25 The present invention provides a novel pharmaceutically useful carrier for a water-  
insoluble or microencapsulated drug. The pharmaceutical compositions containing the  
carrier and the drug are capable of being dispersed rapidly when added to water or an  
aqueous medium, for example, when poured into water with stirring. The dispersion  
may take place quickly, for example, generally within a period of 30 seconds, preferably  
30 within a period of 20 seconds. The invention is associated with a number of advantages.  
One advantage is that the invention may be carried out in a manner that avoids lump  
formation when the pharmaceutical composition is added to water with stirring. A  
second advantage is that there is no need to use an organic solvent in the preparation of  
the pharmaceutical composition. A third advantage is that the pharmaceutical  
35 compositions may be prepared in a simple manner. A fourth advantage is that the  
invention may be carried out relatively cheaply because it permits a high concentration

of thickening agent. The thickening agent is responsible for giving a viscosity sufficient to obtain a homogeneous aqueous suspension of the microcapsules. Because of the high content of thickening agent one may be able to achieve similar dispersion results to prior art compositions with only 1/2 or 1/3 of the suspending granulate. Hence the invention  
5 enables the pharmaceutical compositions to be prepared more cheaply.

The present invention provides a granulate composition useful as a pharmaceutically acceptable carrier. The carrier can be used to prepare water-suspendible pharmaceutical compositions. The granulate composition comprises one or more thickening agents and  
10 one or more disintegrating agents. The granulate composition is adapted to enable pharmaceutical compositions to be converted into homogeneous aqueous suspensions generally within a short period, preferably within 30 seconds, advantageously within 20 seconds, when the pharmaceutical compositions are added to water with agitation, preferably by stirring with a spoon. The pharmaceutical compositions may also be taken  
15 directly in the mouth where they give rise to a suspension of the drug in saliva as aqueous environment.

The granulate composition comprises one or more thickening agents and one or more disintegrating agents. The thickening agent is as defined above in respect of "thickening  
20 or suspending substance". It dissolves in the water and increases the viscosity of the aqueous medium when the pharmaceutical composition is dispersed in water. As examples of thickening agents there may be mentioned xanthan gum, carrageenan, alginates, agar-agar, tragacanth gum, guar gum, carruba gum, karaya gum or modified corn starch. The number of thickening agents chosen for use in the granulate  
25 composition is not critical. A single thickening agent may be chosen.

The granulate composition of the invention also includes one or more disintegrating agents. Disintegrating agents are excipients generally characterised either by a highly cross linked internal structure and a great affinity for water. They have the purpose of  
30 influencing the water uptake and the disintegration time of the pharmaceutical formulation in which they are included. The disintegrating agent preferably operates by driving water into the granulate composition of the invention so as to cause the granulate to swell and burst apart. Thus, in the aqueous medium they operate as dispersing agents that allow the separation of the particle of thickening agent which can rapidly hydrate  
35 and dissolve without forming lumps. The optimal action of the disintegrating agent in achieving separation of the particles of the thickening agent can be obtained and

controlled by adjusting the grade and/or the amount of the disintegrating agent. Although it is possible to use a single disintegrating agent, we prefer to use two or more such agents, advantageously two or three disintegrating agents.

5 As examples of disintegrating agents there may be mentioned alginic acid, carboxymethylcellulose calcium salt, colloidal silicon dioxide, magnesium aluminium silicate, starch and starch derivatives and sodium alginate, sodium starch glycolate, polyvinylpyrrolidone CL (cross-linked) and sodium carboxymethylcellulose CL (cross-linked).

10

We recommend that the ratio of the thickening agent or agents to the disintegrating agent or agents be within the range of 5 to 65 parts by weight, preferably 15 to 55 parts by weight, of thickening agents(s) to 95 to 35 parts by weight, preferably 85 to 45 parts by weight, of disintegrating agent(s). The granulate composition of the invention may consist exclusively of the disintegrating agent(s) and thickening agents. However, it may also contain minor amounts, for example, 0 to 30% by weight, preferably 0 to 20% by weight, of other components. As examples of such other components, there may be mentioned binders, fillers, lubricants, glidants, pharmaceutically acceptable acids, bases or buffers.

20

We recommend that the granulate composition of the invention comprising one of more thickening agents and one or more disintegrating agents has particle sizes within the range of 200 to 850  $\mu\text{m}$ , preferably 250 to 750  $\mu\text{m}$ . A particle size distribution higher than 850  $\mu\text{m}$  may prolong the time necessary to obtain a viscosity sufficient to keep the microcapsules in suspension. On the other hand a case granulate having a particle size distribution lower than 200  $\mu\text{m}$  can lead to lump formation.

25

The following compounds illustrate the substances that may be used as active pharmaceutical agents in pharmaceutical compositions of the invention:

30

Acetylcysteine	Flucloxacillin
Acetylsalicylic Acid	Glaferine
Amitriptyline	Gemfibrozil
Nicardipine	Guaifenesin
Bromazepam	Phenylpropanolamine
35 Fluoxetine	Ibuprofen
Cefalexin	Amitriptyline



- |    |                       |                        |
|----|-----------------------|------------------------|
|    | Lithium Carbonate     | Isosorbide mononitrate |
|    | Cephalosporins        | Etodolac               |
|    | Codeine Phosphate     | Isosorbide dinitrate   |
|    | Caffeine              | Morphine               |
| 5  | 5-aminosalicylic acid | Alkali metal halides   |
|    | Dextro Methorphan     | Ketoprofen             |
|    | Diazepam              | Metoclopramide         |
|    | Penicillins           | Paracetamol            |
|    | Diclofenac            | Ranitidine             |
| 10 | Pancreatin            | Prazosin               |
|    | Diltiazem             | Procainamide           |
|    | Captopril             | Amoxicillin            |
|    | Dipyridamole          | Pseudoephedrine        |
|    | Carboxymethylcystein  | Ambroxol               |
| 15 | Erythromycin          | Timus extract          |
|    | Etofibrate            | Verapamil              |
|    | Furosemide            | Vitamins               |
|    | Cimetidine            | Theophylline           |
- 20 The present invention also provides a process for the preparation of the aforesaid granulate composition which comprises subjecting one or more thickening agents and one or more disintegrating agents to wet granulation with an aqueous medium as wetting agent or dry granulation. The granulate product may then be sieved to conform with the desired particle size distribution. The granulate product obtainable in this way is called
- 25 the "base granulate".
- The base granulate product may be mixed with a water-soluble inert excipient, for example, anhydrous sorbitol, mannitol, sucrose, lactose, fructose, maltodextrine, alanine or pentacrythrite to provide the product with bulk. The excipient preferably has
- 30 sweetening properties. The ratio by weight of the inert excipient to the base granulate is preferably within the range of 0.3 to 5.0, advantageously 1.0 to 4.0.
- The term "suspending granulate" will be used herein to refer to the product of mixing the base granulate with a water-soluble inert excipient or to refer to the base granulate
- 35 product where the base granulate product is to be combined with the active ingredients to make pharmaceutical compositions.

The granulate products of the invention are homogeneously mixed with a pharmaceutically useful substance to prepare pharmaceutical compositions. The pharmaceutically useful substance is a product that is essentially water-insoluble or is coated with a water-insoluble coating or is microencapsulated.


Some materials for making the membranes of microcapsules are selectively water-insoluble at one pH range and water-soluble at another pH range. The granulate compositions of the invention and the pharmaceutical compositions of the invention may therefore include a pH-controlling agent to prevent premature dissolution of the membrane. For instance Eudragit L is a membrane that dissolves at pH 5-6 but does not dissolve at lower pH values. Citric acid is an example of a pH-controlling agent. It may be incorporated in the products of the invention to prevent premature dissolution of the membrane by reducing the pH in the mouth to about 4.

Once the pharmaceutical compositions of the invention have been obtained, the product is preferably divided up into single doses. The individual doses are preferably packaged separately, for example by enclosing each dose in a monodose sachet. The recommended concentration of the active pharmaceutical substance (including the coating or microcapsulating substance, where present) in the overall pharmaceutical composition is preferably within the range of 5% to 50 %, advantageously 8% to 32%, on a weight /weight basis.

The pharmaceutical compositions of the invention are intended for use by suspension in water or an aqueous medium. They can be developed either as formulations to be poured directly into a glass of water, for instance, the formulations defined in the examples as "monodose sachets", or as formulations to be used by taking them directly in the mouth, for instance, formulations defined in the examples as "dry sachets".

The following flow sheet illustrates the manufacturing process of the invention:

## Manufacturing process flow sheet



The invention will be illustrated by the following Examples. Trade marks have been used to give the names of the main ingredients in the Examples.

The chemical names and functions are given below:

Chemical Name	Trade Mark	Function
Xanthan gum	Keltrol™	thickening agent
Carrageenan	Gelcarin™	thickening agent
Sodiumcarboxymethylcellulose CL (cross-linked)	Ac-di-Sol™	disintegrating agent
Cellulose microcrystalline	Avicel™	disintegrating agent
Polyvinylpyrrolidone CL (cross-linked)	Kollidon™	disintegrating agent
Sodium starch glycolate	Explotab™	disintegrating agent
Sorbitol	Karion™	sweetener-diluent

- 5 The base granular is made by wet granulation in the case of Examples 1 to 4 and by dry granulation in the case of Examples 5 to 8.

#### Example 1

##### (A) Preparation of the base granular

- 10 600 g of Keltrol F with particle size less than 150 µm, 300 g of Ac-di-Sol, 300 g of Avicel PH 200 and 600 g of Explotab were mixed in a cube mixer.  
This mixture was loaded into a fluid bed equipped with a rotor insert.  
A granulate was obtained by spraying, at room temperature, on this mixture, 1000 g of an aqueous solution of citric acid (20 % w/w).  
15 Finally the product was dried at 40°C and sieved to give a particle size distribution between 250 µm and 850 µm.

##### (B) Preparation of the suspending granular

- 20 1000 g of (A), with particle size distribution between 210 and 850 mm, were homogeneously mixed with 1875 g of Karion 10 g of Aspartame and 100 g of orange flavour.

(C) Preparation of the monodose sachets

2985 g of (B) were homogeneously mixed with 1430 g of 5-aminosalicylic acid granules coated with Eudragit S and having a potency of 835 mg/g.

- 5 The mixture was divided in sachets each having a weight of 4.437 g and a dosage of 1.2 g.

10	Ingredients	Quantity (mg/sachet)
	5-aminosalicylic acid coated with Eudragit S	1437.2
	Keltrol F	301.5
	Ac-di-Sol	150.7
15	Avicel PH200	150.7
	Explotab	301.5
	Citric acid	100.5
	base granulate	
	suspending granulate	
	Karion	1884.4
20	Aspartame	10.1
	Flavouring agent	100.5
	Total	4437.1
25		

The relatively high weight of each sachet is due to the fact that an unusually large amount of coated drug had to be suspended.

Example 2(A) Preparation of the base granular

- 5 Following the process described in the example 1, a granular (1000g) composed of 300 g of Keltrol F, 300 g of Ac-di-Sol, 300 g of Kollidon CL and 100 g of citric acid, was prepared.

(B) Preparation of the suspending granular

10

1000 g of (A) were mixed, with 2000 g of Karion, 7.0 g of Aspartame and 75 g of orange flavour.

(C) Preparation of the monodose sachets

15

3082 g of (B), were homogeneously mixed with 339 g of Ibuprofen microcapsules having a cellulose acetate phthalate membrane and potency of 909.1 mg/g.

The mixture was divided in sachets each having a weight of 2.220 g and a dosage of 200 mg.

20

Ingredients	Quantity (mg/sachet)
Ibuprofen coated with cellulose acetate phthalate	220.0
Keltrol F	194.7
Ac-di-Sol	194.7
Kollidon CL	194.7
Citric acid	64.9
base granular	
suspending granular	
Karion	1297.8
Aspartame	4.6
Flavouring agent	48.6
Total	2220.0

35

Example 3(A) Preparation of the base granular

- 5 Following the process described in the example 1, a granular (1000g) composed of 200 g of Keltrol F, 300 g of Ac-di-Sol, 250 g of Avicel PH 200, 150 g of Kollidon CL and 100 g of citric acid was prepared.

(B) Preparation of the suspending granular

10

1000 g of (A) were mixed with 2000 g of Karion, 7.0 g of Aspartame and 75 g of orange flavour.

(C) Preparation of the monodose sachets

15

3082 g of (B), were homogeneously mixed with 339 g of Ibuprofen microcapsules having a cellulose acetate phthalate membrane and potency of 909.1 mg/g.

The mixture was divided in sachets each having a weight of 2.220 g and a dosage of 200 mg.

20

Ingredients	Quantity (mg/sachet)
Ibuprofen coated with cellulose acetate phthalate	220.0
Keltrol F	129.8
Ac-di-Sol	194.7
Kollidon CL	97.3
Avicel PH200	162.2
Citric acid	64.9
base granular	
Karion	1297.9
Aspartame	4.5
Flavouring agent	48.7
suspending granular	
Total	2220.0

35

Example 4(A) Preparation of the base granular

Following the process described in the example 1, a granular (1000g) composed of 300 g of Keltrol F, 150 g of Avicel PH 200, 150 g of Ac-di-Sol, 300 g of Explotab, 100 g of citric acid was prepared.

(B) Preparation of the suspending granular

1000 g of (A) were mixed, with 1875 g of Karion, 10 g of Aspartame and 100 g of orange flavour.

(C) Preparation of the monodose sachets

2985 g of (B), were homogeneously mixed with 1124.9 g of coated pellets of Pancreatin, having an Eudragit L membrane and potency of 50.0 UI/mg.

The mixture was divided in sachets each having a weight of 4.131 g and a dosage of 56530 UI.

The relatively high weight of the sachet is due to the unusually large amount of coated drug.

Ingredients	Quantity (mg/sachet)
Pancreatin coated with Eudragit L	1130.6
<div> <div>Keltrol F</div> <div>Ac-di-Sol</div> <div>Avicel PH200</div> <div>Explotab</div> <div>Citric acid</div> </div> <div>base granular</div>	<div>301.5</div> <div>150.7</div> <div>150.7</div> <div>301.5</div> <div>100.5</div>
<div> <div>Karion</div> <div>Aspartame</div> <div>Flavouring agent</div> </div> <div>suspending granular</div>	<div>1884.9</div> <div>10.1</div> <div>100.5</div>
Total	4131.0



-15-

The monodose sachets prepared in the preceding Examples were tested in the following procedure. The contents of one sachet of each Example were poured in a glass of water while stirring with a teaspoon. The details and remarks are shown in the table I.

5 Table I

Example No .	Base granular composition (%)		Monodose sachet weight (g)	Water (ml)	Agitation (seconds)	Suspension characteristics
1	Keltrol	30	4.437	100	20	good
	Ac-di-Sol	15				
	Avicel	15				
	Explotab	30				
	Citric acid.	10				
2	Keltrol	30	2.220	100	20	fairly good
	Ac-di-Sol	30				
	Kollidon	30				
	Citric acid	10				
3	Keltrol	20	2.220	100	20	fairly good
	Ac-di-Sol	30				
	Kollidon	15				
	Avicel	25				
	Citric acid.	10				
4	Keltrol	30	4.131	100	20	good
	Ac-di-Sol	15				
	Avicel	15				
	Explotab	30				
	Citric acid	10				

Example 5(A) Preparation of the base granular

5 333.4 g of Keltrol F with particle size less than 150  $\mu\text{m}$ , 666.6 g of Avicel PH 200, 666.6 g of Explotab, 288.8 g of Ac-di-Sol, were mixed by means of a cube mixer.

After the addition of 44.6 g of Magnesium Stearate as lubricant, the mixture was compressed into large tablets that were then crumbled and granulated with a 850  $\mu\text{m}$  mesh. Finally the mixture was further mixed in a cube mixer.

10

(B) Preparation of the suspending granular

1000 g (A) with particle size distribution between 210 and 850  $\mu\text{m}$ , were mixed in a cube mixer with 1300 g of Karion, previously sieved by 700  $\mu\text{m}$  mesh.

15

(C) Preparation of the monodose sachets

In a cube mixer, 2300 g of (B) were homogeneously mixed with 700 g of Theophylline microcapsules having an ethylcellulose membrane and potency of 900 mg/g. The mixture was divided in sachets each having a weight of 3.00 g and a dosage of 630 mg.

20

Ingredients		Quantity (mg/sachet)
Theophylline coated with ethylcellulose		700.0
Keltrol F	base granular	166.7
Avicel PH200		333.3
Ac-di-Sol		144.4
Explotab		333.3
Mg Stearate		22.3
Karion		1300.0
Total		3000.0

Example 6(A) Preparation of the base granular

- 5 Following the process described in Example 5 a granular (1000 g) composed of 166.7 g of Keltrol F, 166.7 g of Karion, 1444.4 g of Ac-di-Sol, 333.3 g of Explotab, 166.7 g of Avicel PH 200, 22.2 g of Mg Stearate, was prepared.

(B) Preparation of the suspending granular

10

1000g (A), were mixed with 1670 g of Karion.

(C) Preparation of monodose sachets

- 15 2670 g of (B), were homogeneously mixed with 245 g of Cimetidine microcapsules having an ethylcellulose membrane and potency of 816.3 mg/g.  
The mixture was divided in sachets each having a weight of 2.915 g and a dosage of 200 mg.

Ingredients		Quantity (mg/sachet)
Cimetidine coated with ethylcellulose		245.0
Keltrol F	base granular	166.7
Karion		166.7
Avicel PH200		166.7
Ac-di-Sol		144.4
Explotab		333.3
Mg Stearate		22.2
Karion	suspending granular	1670.0
Total		2915.0

Example 7(A) Preparation of base granular

- 5 Following the process described in Example 5, a granular (1000 g) composed of 166.7 g of Gelcarin, 333.3 g of Avicel PH 200, 144.4 g of Ac-di-Sol, 333.3 g of Explotab, 22.2 g of Mg Stearate, was prepared.

(B) Preparation of the suspending granular

10

1000 g of (A), were mixed with 1670 g of Karion.

(C) Preparation of the monodose sachets

- 15 2670 g of (B), were homogeneously mixed with 330 g of Theophylline microcapsules having an ethylcellulose membrane and potency of 900.0 mg.g.  
The mixture was divided in sachets each having a weight of 3.00 g and a dosage of 297 mg.

Ingredients		Quantity (mg/sachet)
Theophylline coated with ethylcellulose		330.0
Gelcarin	base granular	166.7
Avicel PH200		333.3
Ac-di-Sol		144.4
Explotab		333.3
Mg Stearate		22.3
Karion	suspending granular	1670.0
Total		3000.0

-19-

Example 8(A) Preparation of the base granular

- 5 Following the process described in Example 5, a granular (1000 g) composed of 300 g Keltrol F, 130 g of Ac-di-Sol, 300 g of Explotab, 150 g of Avicel PH 200, 100 g of citric acid, 20 g of Mg Stearate, was prepared.

(B) Preparation of the suspending granular

10

1000 g of (A), were mixed with 1000 g of Karion.

(C) Preparation of the monodose sachet

- 15 2000 g of (B), were homogeneously mixed with 880 g of Ibuprofen having a cellulose acetate phthalate membrane and potency of 909.1 mg/g.  
The mixture was divided in sachets each having a weight of 2.880 g and a dosage of 800 mg.

Ingredients		Quantity (mg/sachet)
Ibuprofen coated with cellulose acetate phthalate		880.0
Keltrol F	base granular	300.0
Avicel PH200		150.0
Ac-di-Sol		130.0
Explotab		300.0
Citric acid		100.0
Mg Stearate		20.0
Karion	suspending granular	1000.0
Total		2880.0

-20-

The monodose sachets prepared in the preceding examples were tested in the following procedure. The content of each bag, was poured in a glass of water while stirring with a teaspoon. The details and remarks are shown in the table II.

5 Table II

Example No .	Base granular composition (%)		Monodose sachet weight (g)	Water (ml)	Agitation (seconds)	Suspension characteristics
5	Keltrol	16.7	3.000	50	20	good
	Ac-di-Sol	14.4				
	Avicel	33.3				
	Explotab	33.3				
	Mg Stear.	2.3				
6	Keltrol	16.7	2.915	50	20	good
	Karion	16.7				
	Avicel	16.7				
	Ac-di-Sol	14.4				
	Explotab	33.3				
	Mg Stear.	2.3				
7	Gelcarin	16.7	3.000	50	20	good
	Ac-di-Sol	14.4				
	Explotab	33.3				
	Avicel	33.3				
	Mg Stear.	2.3				
8	Keltrol	30.0	2.880	50	30	fairly good
	Ac-di-Sol	13.0				
	Avicel	15.0				
	Explotab	30.0				
	Citric acid	10.0				
	Mg Stear.	2.0				

The above examples disclose the obtaining of a base granulate product in which the concentration of thickening agent ranges between 16.7% and 30%. In contrast the examples of WO 86/06626 and WO 92/00731 show granulate products having a lower content of thickening agent, namely, ranging between 3.8 to 12.5%.

5

The ability of the aqueous vehicle for keeping the active ingredient in aqueous suspension depends upon the viscosity which in turn depends upon the amount of thickening agent used. Thus, generally speaking, the higher the content of the thickening agent in the base granulate product, the smaller is the amount of base granulate product needed per unit dose of active ingredient. As a result, the lower is the weight of an individual dose of the pharmaceutical composition of the invention. Hence the increased concentration of thickening agent in the case of the invention as mentioned in the previous paragraph is an advantage of the invention.

15 The following two examples concerning two different manufacturing processes to get Dry Sachet formulations.

#### Example 9

Dry sachet formulation deriving from a base granulate made by wet granulation.

20

##### (A) Preparation of the base granulate

According to the process described in example 1, a granulate (1000 g) composed of 300 g of Keltrol F, 300 g of Ac-di-Sol, 300 g of Kollidon CL and 100 g of citirc acid was prepared.

25

##### (B) Preparation of the suspending granulate

1000 g of (A), were mixed with 4000 g of Karion, 4.0 g of Saccharine, 65 g of orange flavour, 45 g of Talc, 1.0 g of Syloid.

30

##### (C) Preparation of the dry sachets

5115 g of (B) were homogeneously mixed with 1611 g of Ibuprofen microcapsules, having a cellulose acetate phthalate membrane and potency of 835.1 mg/g. The mixture was divided in sachets each having a weight of 1.000 g and a dosage of 200 g.

35

.Ingredients	Quantity (mg/sachet)
Ibuprofen coated with cellulose acetate phtalate	239.5
Keltrol F	44.6
Ac-di-Sol	44.6
Kollidon	44.6
Citric acid	14.9
base granulate	
suspending granulate	
Karion	594.7
Saccharine	0.6
Flavouring agent	9.7
Talc	6.7
Syloid	0.1
Total	1000.0

20

Example 10

Dry sachet formulation deriving from a base granulate made by dry granulation

(A) Preparation of the base granulate

25

According to the process described in example 5, a granulate (1000 g) composed of 167 g of Keltrol F, 144 g of Ac-di-Sol, 333 g of Avicel PH 200, 333 g of Explotab and 23 g of Mg Stearate, was prepared.

(B) Preparation of the suspending granulate

30

1000 g of (A), were mixed with 2155 g of Karion, 2 g of saccharine, 37 g of orange flavour, 25 g of Talc.



The above examples disclose the obtaining of a base granulate product in which the concentration of thickening agent ranges between 16.7% and 30%. In contrast the examples of WO 86/06626 and WO 92/00731 show granulate products having a lower content of thickening agent, namely, ranging between 3.8 to 12.5%.

5

The ability of the aqueous vehicle for keeping the active ingredient in aqueous suspension depends upon the viscosity which in turn depends upon the amount of thickening agent used. Thus, generally speaking, the higher the content of the thickening agent in the base granulate product, the smaller is the amount of base granulate product  
10 needed per unit dose of active ingredient. As a result, the lower is the weight of an individual dose of the pharmaceutical composition of the invention. Hence the increased concentration of thickening agent in the case of the invention as mentioned in the previous paragraph is an advantage of the invention.

15 The following two examples concerning two different manufacturing processes to get Dry Sachet formulations.

#### Example 9

Dry sachet formulation deriving from a base granulate made by wet granulation.

20

##### (A) Preparation of the base granulate

According to the process described in example 1, a granulate (1000 g) composed of 300 g of Keltrol F, 300 g of Ac-di-Sol, 300 g of Kollidon CL and 100 g of citric acid was  
25 prepared.

##### (B) Preparation of the suspending granulate

1000 g of (A), were mixed with 4000 g of Karion, 4.0 g of Saccharine, 65 g of orange  
30 flavour, 45 g of Talc, 1.0 g of Syloid.

##### (C) Preparation of the dry sachets

5115 g of (B) were homogeneously mixed with 1611 g of Ibuprofen microcapsules,  
35 having a cellulose acetate phthalate membrane and potency of 835.1 mg/g. The mixture was divided in sachets each having a weight of 1.000 g and a dosage of 200 g.

-22-

Ingredients	Quantity (mg/sachet)
Ibuprofen coated with cellulose acetate phtalate	239.5
Keltrol F	44.6
Ac-di-Sol	44.6
Kollidon	44.6
Citric acid	14.9
base granulate	
suspending granulate	
Karion	594.7
Saccharine	0.6
Flavouring agent	9.7
Talc	6.7
Syloid	0.1
Total	1000.0

20

**Example 10**

Dry sachet formulation deriving from a base granulate made by dry granulation

**(A) Preparation of the base granulate**

25

According to the process described in example 5, a granulate (1000 g) composed of 167 g of Keltrol F, 144 g of Ac-di-Sol, 333 g of Avicel PH 200, 333 g of Explotab and 23 g of Mg Stearate, was prepared.

**(B) Preparation of the suspending granulate**

30

1000 g of (A), were mixed with 2155 g of Karion, 2 g of saccharine, 37 g of orange flavour, 25 g of Talc.

C) Preparation of the dry sachets

3219 g of (B) were homogeneously mixed with 900 g of Ibuprofen microcapsules, having a cellulose acetate phthalate membrane and potency of 831.9 mg/g. The mixture  
5 was divided in sachets each having a weight of 1.100 g and a dosage of 200 g.

Ingredients		Quantity (mg/sachet)
10	Ibuprofen coated with cellulose acetate phtalate	240.4
	Keltrol F	44.6
	Ac-di-Sol	38.5
	Avicel PH 200	88.9
15	Explotab	88.9
	Mg Stearate	6.1
	Karion	575.6
	Saccharine	0.5
20	Flavouring agent	9.8
	Talc	6.7
	Total	1100.0

-24-

CLAIMS

1. A granular composition useful as a pharmaceutical carrier for the preparation of a water-suspendible pharmaceutical composition, comprising one or more thickening agents and one or more disintegrating agents.
2. A granular composition as claimed in claim 1, having particle sizes within the range of 200  $\mu\text{m}$  to 850  $\mu\text{m}$ .
3. A granular composition as claimed in claim 2, having particle sizes within the range of 200  $\mu\text{m}$  to 750  $\mu\text{m}$ .
4. A granular composition as claimed in any one of claims 1 to 3, containing at least one thickening agent selected from xanthan gum, carrageenan, alginates, agar-agar, tragacanth gum, guar gum, carruba gum, karaya gum and modified corn starch.
5. A granular composition as claimed in any one of claims 1 to 4, containing two or more disintegrating agents.
6. A granular composition as claimed in any one of claims 1 to 5, containing at least one disintegrating agent selected from alginic acid, carboxymethylcellulose calcium salt, colloidal silicon dioxide, magnesium aluminium silicate, starch and starch derivatives and sodium alginate, sodium starch glycolate, polyvinylpyrrolidone CL (cross-linked) and sodium carboxymethylcellulose CL (cross-linked).
7. A granular composition as claimed in any one of claims 1 to 6, containing 5 to 65 parts by weight of thickening agent(s) per 95 to 35 parts by weight of disintegrating agent(s).
8. A granular composition as claimed in claim 7, containing 15 to 55 parts by weight of thickening agent(s) per 85 to 45 parts by weight of disintegrating agent(s).
9. A granular composition as claimed in any one of claims 1 to 8, containing up to 30% by weight of at least one other component selected from binders, fillers, lubricants, glidants and pharmaceutically acceptable acids, bases and buffers.

10. A process of preparation of a compound as claimed in any one of claims 1 to 9, which comprises subjecting one or more thickening agents and one or more disintegrating agents to wet granulation with an aqueous medium or dry granulation.
11. A suspending granular product comprising a homogeneous mixture of a granular composition as claimed in any one of claims 1 to 9 and a water-soluble inert excipient.
12. A suspending granular product as claimed in claim 11, wherein the excipient is a sweetening agent.
13. A suspending granular product as claimed in claim 11, wherein the excipient is selected from anhydrous sorbitol, mannitol, sucrose, lactose, fructose, maltodextrine, alanine and pentacrythrite.
14. A process of preparation of a suspending granular product as claimed in claim 11 which comprises mixing a granular composition as claimed in any one of claims 1 to 9 with a water soluble inert excipient.
15. A water-suspensible pharmaceutical composition comprising
  - (a) a granular composition as claimed in any one of claims 1 to 9 or a suspending granular as claimed in any one of claims 11 to 13 and
  - (b) a pharmaceutical that is essentially water-insoluble or coated with a water-insoluble coating or microencapsulated.
16. A pharmaceutical composition as claimed in claim 15, which forms a homogeneous aqueous suspension within 20 seconds when a dose is added to water with agitation.
17. A pharmaceutical composition as claimed in claim 15 or 16, containing at least one of the following as pharmaceutically active substance:

-26-

Acetylcysteine	Flucloxacillin
Acetylsalicylic Acid	Glafeine
Amitriptyline	Gemfibrozil
Nicardipine	Guaifenesin
Bromazepam	Phenylpropanolamine
Fluoxetine	Ibuprofen
Cefalexin	Amitriptyline
Lithium Carbonate	Isosorbide mononitrate
Cephalosporins	Etodolac
Codeine Phosphate	Isosorbide dinitrate
Caffeine	Morphine
5-aminosalicylic acid	Alkali metal halides
Dextro Methorphan	Ketoprofen
Diazepam	Metoclopramide
Penicillins	Paracetamol
Diclofenac	Ranitidine
Pancreatin	Prazosin
Diltiazem	Procainamide
Captopril	Amoxicillin
Dipyridamole	Pseudoephedrine
Carboxymethylcystein	Ambroxol
Erythromycin	Timus extract
Etofibrate	Verapamil
Furosemide	Vitamins
Cimetidine	Theophylline

18. A pharmaceutical composition as claimed in any one of claims 15 to 17 which is in the form of individual doses.

# INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 97/05863

**A. CLASSIFICATION OF SUBJECT MATTER**

IPC 6 A61K9/00 A61K9/20 A61K9/16

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 4 886 669 A (KIMON VENTOURAS) 12 December 1989 see the whole document -----	1-18

☐ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

\* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

19 February 1998

Date of mailing of the international search report

27/02/1998

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Ventura Amat, A

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 97/05863

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 4886669 A	12-12-89	AU 603624 B	22-11-90
		AU 8182387 A	02-06-88
		DK 619987 A	28-05-88
		EP 0273005 A	29-06-88
		JP 63211224 A	02-09-88
<hr/>			